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Abstract: Proteomic patterns derived from mass spectrometry have recently been put forth as potential biomarkers for the 
early diagnosis of cancer. This approach has generated much excitement, particularly as initial results reported on SELDI 
proﬁ  ling of serum suggested that near perfect sensitivity and speciﬁ  city could be achieved in diagnosing ovarian cancer. 
However, more recent reports have suggested that much of the observed structure could be due to the presence of experi-
mental bias. A rebuttal to the ﬁ  ndings of bias, subtitled “Producers and Consumers”, lists several objections. In this paper, 
we attempt to address these objections. While we continue to ﬁ  nd evidence of experimental bias, we emphasize that the 
problems found are associated with experimental design and processing, and can be avoided in future studies.
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Background
Proteomic patterns derived from mass spectrometry have recently been put forth as potential biomarkers 
for the early diagnosis of cancer. Most of the attention has focused on the variant of mass spectrometry 
known as SELDI-TOF (surface-enhanced laser desorption and ionization time-of-ﬂ  ight) applied to 
samples derived from easily available biological ﬂ  uids such as serum or urine. This approach has 
generated much excitement, particularly in light of results initially reported in The Lancet (Petricoin 
et al. 2002), suggesting that near perfect sensitivity and speciﬁ  city could be achieved in diagnosing 
ovarian cancer using serum samples. In addition to publishing these initial results, the NCI/FDA 
Clinical Proteomics Program has also made the raw spectra they used available on their web site: http:// 
home.ccr.cancer.gov/ ncifdaproteomics/ppatterns.asp. The data from the initial study were soon followed 
by data from two further SELDI serum studies on ovarian cancer, and most recently, by more high-
resolution data derived from a different type of mass spectrometry (Qstar-TOF). In all cases, the posted 
results match or exceed those from the initial study. These latter datasets have now served as the basis 
for further papers showing various ways in which ever better separation between cancers and controls 
can be achieved (e.g., Alexe et al. 2004, Zhu et al. 2003, Conrads et al. 2003,2004).
Recently, however, two groups (Sorace and Zhan 2003, Baggerly et al. 2004a) have independently 
noted that much of the structure present may be due to experimental artifacts that could be introduced, 
for example, by imperfect randomization of the order in which the samples were run. If this interpreta-
tion is correct, then structure associated with bias could confound any meaningful biological information 
contained in the spectra. In the presence of confounding, said ovarian spectra cannot be accepted as 
proof that proteomic proﬁ  ling can reliably be used for cancer identiﬁ  cation.
In response, the NCI/FDA group has issued a rebuttal (Petricoin et al. 2004) listing several objections 
to the ﬁ  ndings of bias. The rebuttal notes that these ﬁ  ndings “highlight the dangerous potential for error 
propagation that may arise if a disconnect is allowed to exist between the data producers and the data 
consumers”. The authors suggest that in order to “prevent the dissemination of inaccuracies and speculative 
conclusions, we believe that the producers of genomic and proteomic data should be intercalated more 
fully into the publication process, particularly when the focus of the publication is the analysis of data 
that the submitting authors have not generated”. This rebuttal has appeared in print as a commentary to 
the article of Sorace and Zhan (2003), and we refer to it in this article as “Producers and Consumers”.10
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Our goal is to address the points made in 
“Producers and Consumers”, speciﬁ  cally those that 
relate to issues raised in Baggerly et al. (2004a). 
We do not dispute that one can mathematically 
analyze these spectra and ﬁ  nd algorithms which 
differentiate cancer and control spectra. Rather, we 
contend that differences between cancer and con-
trol spectra can arise from factors that are not 
biologically relevant if great care is not taken with 
the design of the study.
To clarify the notation, we note that there are 
three SELDI ovarian data sets under discussion:
  •    DS1: The initial data from the Lancet article,
  •    DS2: A second set of spectra derived from 
the same biological samples, but run on a 
different chip type, and
  •    DS3: A third set of spectra derived from 
new biological samples but run on the same 
chip type as DS2.
All of the data are available from http://home.
ccr.cancer.gov/ncifdaproteomics/ppatterns.asp.
Objections and Responses
We will now try to address the speciﬁ  c objections 
identiﬁ  ed in “Producers and Consumers”. The 
objections presented in “Producers and Consum-
ers” that relate to points made by Baggerly et al. 
(2004a) are itemized below. After each, we respond 
with emphasis on our main contention: that the 
structure in these data are just as likely to reﬂ  ect 
experimental bias as they are to reﬂ  ect meaningful 
biological patterns of protein expression.
1. Findings in the low M/Z range 
are dangerous
The ﬁ  rst group of objections relates to discussions 
of ﬁ  ndings in the low m/z range of the proteomic 
spectra, and thus primarily concern DS3.
Both Sorace and Zhan (2003) and Baggerly 
et al. (2004a) noted that it was possible to perfectly 
separate cancer spectra from control spectra in DS3 
using the intensities at just two m/z values: 
2.79 and 245.2. Both of these values are in regions 
of the spectra that can be very unstable in a medium 
mass-range (m/z 0-20000) SELDI scan, so the 
strength of the separation was taken as prima facie 
evidence of non-random processing (bias).
However, as noted in “Producers and Consumers”:
  •    it can be dangerous to read much into 
structure found at very low m/z values in 
these scans, as such m/z values are outside 
the range of the calibrants used;
  •    if the cancer and control samples were 
randomized, then systematic biases associ-
ated with machine jitter should be pre-
cluded;
  •    there may be structure in the low mass 
proteome which could generate separating 
structure;
  •    extension of the presence of bias at 2.79 to 
the rest of the dataset or to other datasets 
is “judgmentally biased”.
In general, we agree that using trusting intensi-
ties at m/z values outside of the calibration range 
is a bad idea if one is seeking accurate classiﬁ  ca-
tion. The m/z values will not be well measured, 
making later identiﬁ  cation of the peptides involved 
harder, and we may be looking at regions affected 
by matrix noise (small particles not associated with 
the samples themselves) if we get to very low m/z 
values (as we do here). We note, however, that such 
values were used for classiﬁ  cation in both the 
initial Lancet publication and with the initial post-
ings of the raw data.
Nonetheless, we think that attempts to classify 
spectra using readings “outside the range” are valu-
able as negative tests, in part so that we can see 
how much better our predictions are when we think 
that some structure should be present than when 
we think none exists. This is the sense in which we 
made use of these low m/z intensities.
With respect to randomization in DS3, “Producers 
and Consumers” notes that “if the investigators would 
have contacted us, we could have elaborated, as 
previously stated on our website, that the SELDI-TOF 
MS data was produced by randomly commingling 
cases and controls. On any given 8 spot ProteinChip 
array, both cases and controls were applied in random 11
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spot locations”. Thus, they maintain that the values 
at 2.79 cannot be due to bias.
In general, we agree that proper randomization of 
the type described should preclude biases associated 
with a nonrandom sample distribution. However, 
whatever was previously stated, the website now 
(Dec 2004) states that the samples “were not 
randomized so that we could evaluate the effect of 
robotic automation” (emphasis ours). Further, we 
note that an identical comment about randomly com-
mingling cases and controls was made in the Lancet 
paper with regard to DS1. One of the ﬁ  ndings of 
Baggerly et al. (2004a) was that a subset of these 
samples had clearly not been randomized. This 
finding was not addressed in “Producers and 
Consumers”.
Having discounted bias, “Producers and 
Consumers” concludes that the observed structure 
must be due to real biology associated with the low-
mass proteome, which is currently not well under-
stood. While we concede that the low mass proteome 
has yet to be fully explored, we note that this explana-
tion still seems odd with respect to the peak at 2.79. 
The signal is very weak, and there are no other peaks 
nearby in the spectrum. Even a metabolite should have 
a mass on the order of a single amino acid, and in this 
mass range there should be other artifacts present.
However, the assumption that the low m/z ﬁ  nd-
ings must be biologically relevant rests on the 
assumption that the data were randomized 
(addressed above). Rejection of the prior assump-
tion of randomization means that the differences 
may be due to biology, or they may be due to 
artifacts; the situation is indeterminate.
Then there is the issue of our judgement. In 
discussing the structure found in DS3, “Producers 
and Consumers” notes that Sorace and Zhan’s 
(2003) interpretation of bias at m/z 2.79 is extended 
to “the entire SELDI-TOF MS data set, including 
many other datasets that they did not in fact ana-
lyze”, and that these “broad conclusions are judg-
mentally biased and scientiﬁ  cally unfounded”.
We fail to see how extending the presumption 
of bias to the rest of the data set is judgmentally 
biased or even avoidable. Certainly with DS3, 
if structure at 2.79 shows that the samples were 
processed differently in some way, that difference 
should be expected to persist for all m/z values.
As to the latter part of the assertion regarding 
the other datasets, all three datasets are surveyed 
in Baggerly et al. (2004a), and the assertions of 
bias there are based on the analysis of all three.
As our calculations are publicly available, we 
invite the scientiﬁ  c community to reproduce them 
in sufﬁ  cient detail to be satisﬁ  ed that they are not 
“scientiﬁ  cally unfounded”.
There is a ﬁ  nal semantic issue of whether we are 
confusing “noise” with “bias” in our investigations 
of the low m/z region. As we see it, areas where 
only “noise” (complete lack of structure) is expected 
can, if they show such unexpected structure, suggest 
“bias”, e.g. in the form of nonrandom sample 
allocation to spots or differential preprocessing.
The producers also raise other objections that 
encompass DS1 and DS2 as well.
2. The SOP the producers follow with respect
to calibration means that the data are correctly 
calibrated
“Producers and Consumers” notes that while 
Baggerly et al. (2004a) “wondered .. about our 
calibration method, we adhere to strict SOPs 
whereby any TOF MS is calibrated at the beginning 
of every analysis”.
We do not dispute that a strict SOP was followed 
for calibration. However, we believe that the posted 
values are wrong. The posted spectra show m/z 
values corresponding to the default calibration that 
ships with the SELDI software. To us, this mistake 
suggests an error in ﬁ  le export rather than a failure 
to attempt calibration, but an error, nonetheless. 
We have encountered this type of problem our-
selves, when we meant to “apply” a calibration 
equation to all spectra in a set. We accidentally 
clicked a bit early, and the calibration was applied 
only to the one clicked spectrum. Consequently, 
we check both for consistency and for numbers 
associated with the default settings.
As further evidence that a calibration problem 
exists, we note that in Conrads et al. (2003), where 
the NCI/FDA Qstar spectra were ﬁ  rst described, 12
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Figure 4 of that paper shows Qstar and SELDI 
spectra derived from the same SELDI chip. The 
chips used for the Qstar experiment were of 
the same type as those used in DS2 and DS3. In 
the Conrads et al. (2003) ﬁ  gure, the maxima of the 
SELDI and Qstar spectra are roughly aligned, and 
we believe that the alignment shown there is 
correct. However, if we superimpose the location 
of the biggest SELDI peak from the Conrads et al. 
(2003) picture on a plot of the average cancer 
spectra from DS2 and DS3, we note that the 
posted maxima are hundreds of units away. This 
is shown in Figure 1a of this response. If we use 
the marked peaks in the Conrads et al. (2003) 
SELDI ﬁ  gure to supply an external calibration for 
DS2 and DS3, the peak locations are aligned even 
at m/z values not used in the calibration, as shown 
in Figure 1b.
One more indicator can be derived from the DS3 
spectra. The overall maximum peak is located at 
m/z 7966 in the average cancer spectrum. Due to 
the occurrence of multiple charge states (the 
peptide capturing 2 protons instead of 1), we would 
expect to see a corresponding peak near m/z 3983. 
This peak is visible, but at m/z 3993.
The effect of using the default calibration is not 
slight. The m/z values for DS3 are off by about 
2.5% in the vicinity of the biggest peak, and the 
m/z values for DS2 are off by about 3.9%. As the 
SELDI results are nominally accurate to within a 
few tenths of a percent, miscalibration this severe 
can actively mislead investigators performing 
database searches based on the reported m/z 
values.
3. One group can ﬁ  nd transcendent structure, 
and another cannot
“Producers and Consumers” notes that while 
Baggerly et al. (2004a) noted “the inability of 
features to transcend separate data sets”, a second 
article by Zhu et al. (2003) “concluded that tran-
scendent features could be found”. The producers 
cite the latter publication as evidence that DS2 and 
DS3 contain reproducible biological structure.
Baggerly et al. (2004a) assumed that the errors 
in calibration described above should preclude the 
persistence of biological structure across datasets. 
We verified that the patterns supplied on the 
NCI/FDA web site did not represent reproducible 
structure across DS2 and DS3. But, given the off-
set, we did not conduct an exhaustive search. On 
the other hand, Zhu et al. (2003) noted that when 
the 18 m/z values that were chosen to separate 
cancers from controls in DS2 were used in DS3, 
perfect separation was observed even though DS3 
had been treated as a blinded test set.
Figure 1: (a) The average cancer spectra 
from DS2 and DS3, with the location of 
the maximum peak from Conrads et al. 
(2003) shown. The posted spectra appear 
offset. (b) The corresponding average 
spectra after using the labeled peaks in 
the Conrads et al. (2003) ﬁ  gure to recali-
brate the spectra. Agreement between 
DS2 and DS3 is now good throughout the 
region bracketed by calibrants.
Average Cancer Spectra for DS2 (blue) and DS3 (red), initial calibration 
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This apparent contrast can in fact be easily 
resolved. The exact approach is detailed in Baggerly 
et al. (2005), but the key point is simply that DS3 
is so easy to correctly classify that near-perfect 
separation results are obtained using 18 m/z values 
chosen completely at random.
Thus, biology is not required to explain the 
separation observed. Further, when the patterns of 
protein expression at the 18 m/z values supplied are 
checked in both DS2 and DS3, the directionality of 
expression changes for 13 of the 18: if expression 
is higher in cancers in DS2, it is higher in controls 
in DS3. This suggests that a biological explanation 
is not only unnecessary to explain the ﬁ  ndings in 
Zhu et al. (2003), it is actively precluded.
4. The focus of the objections has been the
SELDI data, not the Qstar data
The focus of the analysis in both Sorace and 
Zhan (2003) and Baggerly et al. (2004a) was on 
the ovarian SELDI data. However, the producers 
feel that the more recent high-resolution Qstar 
data is the current state of the art, and they sug-
gest that more attention should be paid to the 
better data.
This observed focus is not due to a lack of inter-
est in the Qstar data, but rather to the time lag 
associated with publication. However, as the Qstar 
ovarian spectra are derived from SELDI chips, 
biases that affect these chips can affect the Qstar 
data as well, so understanding how experimental 
design issues can affect the SELDI results is still 
relevant. We note that the ﬁ  le names of the DS3 
SELDI spectra are identical to the ﬁ  le names of 
the Qstar spectra, which suggests to us that the DS3 
chips were used in the Qstar experiment. If this is 
in fact the case, biases affecting the DS3 chips are 
even more directly relevant.
Further, while the Qstar data are of higher reso-
lution, they also show signs of experimental bias.
In Figure 2, we show a heat map of all of the 
Qstar spectra we have available, sorted by the ﬁ  le 
names supplied, in the vicinity of m/z 8602. This 
value is identiﬁ  ed in Conrads et al. (2004) as being 
of use for distinguishing ovarian cancer patients 
from healthy controls, and a higher level of 
expression is observed for the cancer patient spectra. 
However, there is also a visible peak roughly 80 units 
lower in which expression is high for healthy 
women but for just half of the cancer patients. As 
noted in Baggerly et al. (2004b), there is a simple 
explanation: all of the controls were run before all 
of the cancers, and a machine breakdown preferen-
tially affected spectra run later in the process.
Figure 2: A heat map of the Qstar spectra 
we have available, sorted by ﬁ  le name, in 
the vicinity of m/z 8602. This m/z value is 
identiﬁ  ed on the NCI/FDA website as use-
ful for separating healthy women from 
ovarian cancer patients, and this separa-
tion is visible. However, roughly 80 Da 
below, there is a peak that serves to 
separate the healthy women and the ﬁ  rst 
half of the ovarian cancer patients from 
the second half of the ovarian cancer 
patients.
Heat Map of 216 Qstar Spectra Near Best Split 
M/Z 
Cancer 2 
Cancer 1 
Normal
8523.27 8601.511 14
Baggerly, Coombes, and Morris
Cancer Informatics 2005:1 
In response, Liotta et al. (2004) state that “the 
experimental design element that they highlight in 
their criticism was explicitly planned into the study 
we reported ... We have never claimed or intimated 
that the samples were randomized and/or co-mingled 
in the initial experimental design”. (Emphasis ours.)
In our view, however, claims of 100% sensitiv-
ity and speciﬁ  city (as made in Conrads et al. 2004) 
have meaning only if known sources of variation 
such as run order have been balanced or random-
ized. Such claims can be actively misleading if one 
has chosen to completely confound an effect of 
interest (cancers vs controls) with run order rather 
than to randomize.
Concluding Remarks
The producers have claimed that the consumers 
are mistaken as to the presence of bias. We respect-
fully disagree. We are willing to revise our beliefs 
when features in the data that refute our claims are 
presented. Until that time, we must repeat our 
initial position: No one disputes that structure can 
be found in all of these datasets. However, the 
structure appears to be associated with strong evi-
dence of experimental bias. As such, the demon-
stration of structure does not constitute proof that 
these spectra can be used for clinically meaningful 
tasks such as the diagnosis of cancer.
We emphasize, however, that the problems 
described herein are associated with experimental 
design and analysis techniques, and not with the 
proteomic technology. With careful design, bias 
and confounding can be avoided.
In the context of design, we feel that the problems 
noted to date strongly suggest the need for standards 
on incorporating information such as run order and 
clinical information into the reporting of proteomic 
data. The Microarray Gene Expression Data Society 
(MGED) has developed such a standard for micro-
array data: the Minimum Information About a 
Microarray Experiment (MIAME; Brazma et al. 
2001, Spellman et al. 2002). Exactly what should 
be supplied in the proteomic equivalent is, we 
believe, a productive area for debate. Indeed, this 
was also the consensus of the participants at the Early 
Detection Research Network (EDRN) meeting on 
the analysis of SELDI/MALDI data (Seattle, 2004). 
In the interim, we note with respect to SELDI that 
current versions of the Ciphergen software support 
exporting the data in an XML format that could serve 
as a template for an eventual standard.
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